Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;16(14-15):925-935.
doi: 10.1080/1750743X.2024.2383554. Epub 2024 Aug 9.

The role of nemolizumab in the treatment of atopic dermatitis for the adult population

Stuti Prajapati  1 , Joseph P Flemming  2 , Danyaal Khan  2 , Haowei Han  3 , Brian How  3 , Suzanne Sirota Rozenberg  3 , Steven R Feldman  1
Affiliations
Review

The role of nemolizumab in the treatment of atopic dermatitis for the adult population

Stuti Prajapati et al. Immunotherapy. 2024.

Abstract

Atopic dermatitis (AD) often requires long-term treatment that may be associated with adverse effects. This review aims to characterize nemolizumab as a treatment for AD in adults. A literature search was performed to assess nemolizumab's role in moderate-to-severe AD in adults. Currently, clinical trials are being conducted to evaluate the clinical efficacy, safety profile and optimal dosing of nemolizumab for adults with moderate-to-severe AD. The most common adverse effects include nasopharyngitis, AD exacerbation and increased blood creatinine phosphokinase. Recent data from clinical trials suggest nemolizumab may be an acceptable treatment in adults with moderate-to-severe AD.

Keywords: IL-31; atopic dermatitis; eczema; immunotherapy; pruritus; systemic treatment.

Plain language summary

Atopic dermatitis, also known as eczema, is a long-lasting skin condition that is difficult to treat. Symptoms include itching, redness, dryness and pain. Various eczema treatments are available to help patients based on how severe their symptoms are. Nemolizumab is a treatment that blocks immune system pathways involving itching and inflammation. This review describes nemolizumab as a treatment option for moderate-to-severe eczema in adults. We completed a literature search to understand nemolizumab's role in eczema treatment. Nemolizumab has decreased itchiness in adults with moderate-to-severe eczema in clinical trials. The most common side effects of nemolizumab treatment were the common cold, worsening of eczema and an increased muscle marker (creatinine phosphokinase). Nemolizumab appears to be an effective treatment for moderate-to-severe eczema in adults with bearable side effects.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.

Figures

Figure 1.
Figure 1.
Mechanism of action for nemolizumab. AKT: Protein kinase B; IL-31: Interleukin-31; IL-31Rα: Interleukin-31 alpha receptor; JAK/STAT: Janus kinase/signal transducers and activators of transcription; MAPK: Mitogen-activated protein kinase; OSMRB: Oncostatin Mβ receptor; PI3K: Phosphoinositide-3-kinase.
See this image and copyright information in PMC

References

    1. Sroka-Tomaszewska J, Trzeciak M. Molecular mechanisms of atopic dermatitis pathogenesis. Int J Mol Sci. 2021;22(8):4130. doi: 10.3390/ijms22084130 - DOI - PMC - PubMed
    1. Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40(2):84–92. doi: 10.2500/aap.2019.40.4202 - DOI - PMC - PubMed
    1. Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21–40. doi: 10.1038/s41573-021-00266-6 - DOI - PMC - PubMed
    1. Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583–590. doi: 10.1016/j.jid.2018.08.028 - DOI - PubMed
    1. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527–1534. doi: 10.1038/jid.2013.446 - DOI - PubMed

Publication types

Substances

LinkOut - more resources